Treatment modalities that have been extrapolated from ccRCC such as VEGF- or mTOR-targeting agents have been explored in metastatic nccRCC, however, with suboptimal results (16, 17). The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.